Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > FDA applications ???

<< Previous

Bullboard Posts

Next >>

Post by MrMugsyon May 02, 2022 9:14am

257 Views

Post# 34647047

FDA applications ???

With CITA scratched of the "to do" list ... seems fast-track and/or breakthrough therapy designation applications should be filled out before fall. Thinking we'll have the information required to do so.

Maybe a few words about fast-track tomorrow ? Would be nice.

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale